Listed by the USPTO as ABDALHAMEED, MANAHIL MIRGHANI ALI
Tech Center 1600 • Art Units: 1622 1625 1629
This examiner grants 50% of resolved cases
ABDALHAMEED, MANAHIL MIRGHANI ALI works in Tech Center 1600 and Art Unit 1622. The profile includes 153 resolved cases, a 50.3% allowance rate, and a median of 1041 days to allowance. The 39.1% interview lift indicates that interviews are strongly associated with improved allowance outcomes in this record.
Ribon Therapeutics Inc., Compass Pathfinder Limited, and Mindset Pharma Inc. are the leading companies represented. The leading firms are COOLEY LLP, AMIN, TUROCY & WATSON, LLP, and Apex Attorneys at Law, LLP. Practitioners may find interview-based prosecution especially relevant, while the allowance rate and median timing indicate that cases may require sustained attention through examination.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18282424 | NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE | Final Rejection | The Regents of the University of Michigan |
| 19568483 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Final Rejection | MINDSET PHARMA INC. |
| 18391748 | CRYSTALLINE FORM OF AN MDM2-p53 INHIBITOR AND PHARMACEUTICAL COMPOSITIONS | Final Rejection | Boehringer Ingelheim International GmbH |
| 18578783 | OCTENIDINE COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Solventum Intellectual Properties Company |
| 18726838 | PROCESS FOR ISOLATING 2,4-BIS-(2,4-DIHYDROXYPHENYL)-6-(4-METHOXYPHENYL)-1,3,5-TRIAZINE (DIOPAT) | Non-Final OA | BASF SE |
| 18390242 | COMPOSITIONS AND METHOD FOR TREATING GUT PERMEABILITY CAUSED BY HYDROGEN SULFIDE PRODUCING BACTERIA | Non-Final OA | The United States Government as represented by the Department of Veterans Affairs |
| 18259843 | Methods of Treatment | Non-Final OA | Arena Pharmaceuticals, Inc. |
| 17801486 | TREATMENT FOR CHEMOBRAIN | Final Rejection | YALE UNIVERSITY |
| 18556456 | COMPOUNDS FOR USE IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Final Rejection | INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS |
| 17808476 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | Non-Final OA | YODA THERAPEUTICS INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy50.3% of resolved applications examined by Manahil Mirghani Ali Abdalhameed were allowed (153 resolved cases), compared with 60.6% across Art Unit 1622 over the last five years.
This examiner's interview lift is +39.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Manahil Mirghani Ali Abdalhameed took 1,041 days on average from filing to allowance.
Manahil Mirghani Ali Abdalhameed examines applications in Art Unit 1622 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
